Corbus Pharma Aligns with FDA on CRB-701 Path; CRB-913 Study Enrolls
Corbus Pharmaceuticals announced significant progress in its oncology and obesity programs. The company reached broad alignment with the FDA on the registration path for CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancer, with updated data to be presented at ASCO 2026 and a registrational study for 2L HNSCC starting this summer. Additionally, Corbus completed enrollment for its CRB-913 CANYON-1 Phase 1b study for obesity, with topline data anticipated this summer. For Q1 2026, the company reported a net loss of $23.0 million, an increase from $17.0 million in Q1 2025, primarily due to higher clinical development expenses. Corbus maintains a strong cash position of $138.2 million, expected to fund operations into 2028.
Key Highlights
- Corbus Pharma reached broad alignment with the FDA on the registration path for CRB-701 in HNSCC and cervical cancer.
- Updated CRB-701 monotherapy data in HNSCC and cervical cancer to be presented at ASCO 2026.
- Registrational study for CRB-701 in second-line HNSCC is on track to start this summer.
- Completed enrollment in the 16-week CANYON-1 study (n=240) of CRB-913 for obesity.
- Topline data from the CRB-913 CANYON-1 Phase 1b study expected this summer.
- Q1 2026 net loss was $23.0 million, compared to $17.0 million in Q1 2025.
- Operating expenses increased to $24.3 million in Q1 2026 from $19.8 million in Q1 2025.
- Cash, cash equivalents, and investments totaled $138.2 million as of March 31, 2026, funding operations into 2028.